During his 35 years with the Cystic Fibrosis Foundation -- 21 years as its president and CEO -- Beall has had a profound impact on the lives of people with CF. Under his leadership, the Foundation has achieved unprecedented gains in research, treatment and care, and as a result people with CF are living longer, healthier lives than ever before. When Beall joined the Foundation in 1980, the median predicted age of survival for a person with the disease was 18 years of age -- today it is more than 40 years. For the first time ever, more than 50 percent of people with CF are over 18 years of age. CF is no longer a pediatric disease.
“We are profoundly grateful for Dr. Beall’s leadership and in awe of his many accomplishments. During his more than three decades with the Foundation, he has had a transformative impact on the CF community,” said Catherine C. McLoud, chair of the CF Foundation Board of Trustees. “It would be difficult to find another nonprofit leader who has made such a dramatic difference in the lives of people with a disease, and nobody beats Dr. Beall’s record of innovation and passionate commitment to our mission.”
Beall inspired the Foundation’s long-standing Research Development Program, a dynamic, interdisciplinary research network that laid the groundwork for the discovery of the CF gene in 1989. In 1997, he established the Foundation’s Therapeutics Development Program, a unique coalition that has advanced CF drug development through a centralized network of clinical trials and alliances with biotech companies. Beall also pioneered the Foundation’s successful venture philanthropy model, which has been a game changer in CF research and development.
Dr. Beall’s revolutionary approach to research is responsible for a continuum of breakthrough CF treatments, including Kalydeco™ and the recently approved Orkambi™, both of which address the underlying cause of the disease.
A CF trailblazer in his own right, Dr. Campbell has worked side by side with Dr. Beall for nearly two decades, joining the Foundation in 1998 as executive vice president for medical affairs. In addition to overseeing the Foundation’s research and drug discovery and development efforts, Campbell directs its clinical research program, network of care centers and national patient registry database.
An accomplished pediatric pulmonologist, Campbell previously served as center director at the Vanderbilt University CF Care Center, where he expanded the program from 30 patients to more than 300 in just five years. Until recently, he continued to provide direct clinical care to patients at the Johns Hopkins CF Care Center.
Dr. Beall and Dr. Campbell will work closely together to provide for a seamless transition of leadership and ensure the Foundation’s strong momentum continues.
Additional Resources:
Read Dr. Beall's letter to the CF communityRead Catherine McLoud's letter to the CF community